Kyverna Therapeutics Inc
KYTX
NASDAQ
Biotechnology
$8.17
USD
+0.09 (+1.11%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $479.67M
Volume 579.9K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-152.64M
TTM
+3.8%
YoY
Operating Cash Flow
$-158.75M
TTM
-12.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 8.6 | 8.3 | 9.3 | 11.3 | 14.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 44.4 | 38.7 | 39.3 | 41.4 | 39.6 |
Operating Income | -44.4 | -38.7 | -39.3 | -41.4 | -39.6 |
EBITDA | -43.9 | -38.3 | -38.9 | -41.0 | -39.1 |
Other Income / Expense | -0.0 | -0.1 | 0.0 | -0.0 | -0.0 |
Total Other Income / Expense | 2.3 | 1.9 | 1.5 | 1.6 | 1.2 |
Income Before Income Taxes | -42.1 | -36.8 | -37.8 | -39.7 | -38.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -42.1 | -36.8 | -37.8 | -39.7 | -38.3 |
Consolidated Net Income / Loss | -42.1 | -36.8 | -37.8 | -39.7 | -38.3 |
Net Income Attributable to Common Shareholders | -42.1 | -36.8 | -37.8 | -39.7 | -38.3 |
Basic EPS | -$0.97 | -$0.85 | -$0.80 | -$0.66 | -$0.63 |
Diluted EPS | -$0.97 | -$0.85 | -$0.80 | -$0.66 | -$0.63 |
Basic Shares Outstanding | 43.2M | 43.4M | 47.2M | 60.4M | 60.9M |
Diluted Shares Outstanding | 43.2M | 43.4M | 47.2M | 60.4M | 60.9M |